...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cellular and molecular medicine. >In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis
【24h】

In‐depth proteomics approach reveals novel biomarkers of cardiac remodelling after myocardial infarction: An exploratory analysis

机译：深入的蛋白质组学方法揭示心肌梗死后心肌重塑的新型生物标志物：探索性分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cardiac remodelling following myocardial infarction (MI) is a maladaptive change associated with progressive heart failure and compromises long‐term clinical outcome. A substantial proportion of patients afflicted by MI still develop adverse outcomes associated with cardiac remodelling. Therefore, it is crucial to identify biomarkers for the early prediction of cardiac remodelling. An in‐depth proteomics approach, including both semi‐quantitative and quantitative antibody arrays, was used to identify circulating biomarkers that may be associated with detrimental cardiac remodelling. Furthermore, statistical correlation analysis was performed between the candidate biomarkers and clinical cardiac remodelling data to demonstrate their clinical utility. A systematic proteomics approach revealed that sclerostin (SOST), growth differentiation factor‐15 (GDF‐15), urokinase‐type plasminogen activator (uPA), and midkine (MK) were increased, while monocyte chemotactic protein‐3 (MCP‐3) was uniquely decreased in MI patients who developed cardiac remodelling, compared to MI patients who did not develop cardiac remodelling and healthy humen. Moreover, correlation analyses between serum proteomes and cardiac remodelling echocardiographic parameters demonstrated a moderate positive association between left ventricular end‐diastolic volume index (LVEDVi) and the three serum proteins, uPA, MK and GDF‐15 ( P ?.05, respectively), and a moderate negative correlation between LV ejection fraction (LVEF) and these serum proteins ( P ?.05, respectively). Importantly, uPA and MK were firstly identified to be associated with the development of cardiac remodelling. The present study contributes to a better understanding of the various cytokines expressed during adverse cardiac remodelling. The identified biomarkers may facilitate early identification of patients at high risk of ischaemic heart failure pending further confirmation through larger clinical trials.
机译：心肌梗死后心脏重塑（MI）是与渐进心力衰竭相关的不良改变，妥协长期临床结果。 MI患病的大部分患者仍然发展与心脏重塑相关的不利结果。因此，识别用于早期预测心脏重塑的生物标志物至关重要。一种深入的蛋白质组学方法，包括半定量和定量抗体阵列，用于鉴定可能与有害的心脏重塑相关的循环生物标志物。此外，在候选生物标志物和临床心脏重塑数据之间进行统计相关分析，以证明其临床效用。系统蛋白质组学方法揭示了燃气蛋白（SOST），生长分化因子-15（GDF-15），尿激酶型纤溶酶原激活剂（UPA）和中核（MK），而单核细胞趋化蛋白-3（MCP-3）与没有发育心脏重塑和健康幽默的MI患者相比，在发育心脏重塑的MI患者中独特地降低。此外，血清蛋白质和心脏重塑超声心动图参数之间的相关分析证明了左心室舒张性体积指数（LVEDVI）和三种血清蛋白，UPA，MK和GDF-15之间适度的阳性关联（分别分别为05） ，LV喷射分数（LVEF）与这些血清蛋白质之间的适度负相关（分别为05）。重要的是，首先确定UPA和MK与心脏重塑的发展有关。本研究有助于更好地了解在不良心脏重塑期间表达的各种细胞因子。通过较大的临床试验，所识别的生物标志物可以促进缺血性心力衰竭的高风险患者的早期鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号